Antibodies that bind to EphA2 and methods of use thereof
Provided herein is disclosure about the development and characterization of an antibody that binds to antigen EphA2 which is present on a variety of human cancers from breast, lung, prostate, and colons. Methods of diagnosing and treating various cancers by using such antibodies directed against this antigen are also disclosed.
1. A method of treating cancer in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of an EphA2 antibody that specifically binds to EphA2; wherein the EphA2 antibody comprises the three complementarity determining regions from the heavy chain and the three complementarity determining regions from the light chain of antibody LUCA19 produced by the cell line having ATCC No. PTA-5070.
2. The method of claim 1 , wherein the EphA2 antibody is a humanized antibody.
3. The method of claim 1 , wherein the EphA2 antibody is a chimeric antibody comprising a heavy chain variable region and a light chain variable region from the heavy chain and the light chain variable regions of antibody LUCA19 produced by the cell line having ATCC No. PTA-5070.
4. The method of claim 3 , wherein the chimeric antibody comprises a heavy chain constant region and a light chain constant region from a human antibody.
5. The method of claim 1 , wherein the EphA2 antibody is linked to a therapeutic agent.
6. The method of claim 5 , wherein the therapeutic agent is delivered into a cancer cell.
7. The method of claim 1 , wherein the EphA2 antibody is an antigen-binding fragment selected from the group consisting of a Fab, a Fab′, a F(ab′) 2 and a Fv; and wherein the antigen-binding fragment retains the binding specificity of antibody LUCA19 produced by the cell line having ATCC No. 5070.
8. A method of treating cancer in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of an EphA2 antibody that specifically binds to EphA2; wherein the EphA2 antibody comprises the three complementarity determining regions from the heavy chain and the three complementarity determining regions from the light chain of antibody SPL1 produced by the cell line having ATCC No. PTA-6059.
9. The method of claim 8 , wherein the EphA2 antibody is a humanized antibody.
10. The method of claim 8 , wherein the EphA2 antibody is a chimeric antibody comprising a heavy chain variable region and a light chain variable region from the heavy chain and the light chain variable regions of antibody SPL1 produced by the cell line having ATCC No. PTA-6059.
11. The method of claim 10 , wherein the chimeric antibody comprises a heavy chain constant region and a light chain constant region from a human antibody.
12. The method of claim 8 , wherein the EphA2 antibody is linked to a therapeutic agent.
13. The method of claim 12 , wherein the therapeutic agent is delivered into a cancer cell.
14. The method of claim 8 , wherein the EphA2 antibody is an antigen-binding fragment selected from the group consisting of a Fab, a Fab′, a F(ab′) 2 and a Fv; and wherein the antigen-binding fragment retains the binding specificity of antibody SPL1 produced by the cell line having ATCC No. 6059.
15. A method of treating cancer in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of an EphA2 antibody that specifically binds to EphA2; wherein the EphA2 antibody comprises the three complementarity determining regions from the heavy chain and the three complementarity determining regions from the light chain of antibody LUCA40 produced by the cell line having ATCC No. PTA-6056.
16. The method of claim 15 , wherein the EphA2 antibody is a humanized antibody.
17. The method of claim 15 , wherein the EphA2 antibody is a chimeric antibody comprising a heavy chain variable region and a light chain variable region from the heavy chain and the light chain variable regions of antibody LUCA40 produced by the cell line having ATCC No. PTA-6056.
18. The method of claim 17 , wherein the chimeric antibody comprises a heavy chain constant region and a light chain constant region from a human antibody.
19. The method of claim 15 , wherein the EphA2 antibody is linked to a therapeutic agent.
20. The method of claim 19 , wherein the therapeutic agent is delivered into a cancer cell.
21. The method of claim 15 , wherein the EphA2 antibody is an antigen-binding fragment selected from the group consisting of a Fab, a Fab′, a F(ab′) 2 and a Fv; and wherein the antigen-binding fragment retains the binding specificity of antibody LUCA40 produced by the cell line having ATCC No. 6056.
22. A method of treating cancer in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of an EphA2 antibody that specifically binds to EphA2; wherein the EphA2 antibody comprises the three complementarity determining regions from the heavy chain and the three complementarity determining regions from the light chain of antibody SG5 produced by the cell line having ATCC No. PTA-7356.
23. The method of claim 22 , wherein the EphA2 antibody is a humanized antibody.
24. The method of claim 22 , wherein the EphA2 antibody is a chimeric antibody comprising a heavy chain variable region and a light chain variable region from the heavy chain and the light chain variable regions of antibody SG5 produced by the cell line having ATCC No. PTA-7356.
25. The method of claim 24 , wherein the chimeric antibody comprises a heavy chain constant region and a light chain constant region from a human antibody.
26. The method of claim 22 , wherein the EphA2 antibody is linked to a therapeutic agent.
27. The method of claim 26 , wherein the therapeutic agent is delivered into a cancer cell.
28. The method of claim 22 , wherein the EphA2 antibody is an antigen-binding fragment selected from the group consisting of a Fab, a Fab′, a F(ab′) 2 and a Fv; and wherein the antigen-binding fragment retains the binding specificity of antibody SG5 produced by the cell line having ATCC No. 7356.